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As with many other types of cancer, patients with head and neck squamous cell carcinoma 
(HNSCC) that have not responded to surgery, radiation or chemotherapy, have limited treatment 
options after the disease has spread. A Fred Hutch study published in the journal Clinical Cancer 
Research, led by Russell Moser and Dr. Chang Xu, in the Kemp (Human Biology and Public Health 
Sciences Divisions) and Méndez (Clinical Research Division) labs, respectively, with significant 
contribution by the lab of Dr. Carla Grandori (Human Biology Division), sought to identify new 
therapeutic targets for this disease. 
The tumor suppressor p53 is the most commonly mutated gene in head and neck cancer. Because 
mutations in p53 are common in HNSCC and are associated with metastasis,  resistance to therapy 
and poor patient survival, identifying vulnerabilities of p53 mutant HSNCC is of great clinical 
interest. "Tumors that harbor p53 mutations are more lethal to the patient, yet there are no tailored 
therapies for these tumors," said Dr. Eduardo Méndez.  
To explore such vulnerabilities of HSNCC cells, the investigators performed a short interfering RNA 
(siRNA) screen using 5 HSNCC cell lines derived either from primary or recurrent/metastatic tumors 
that targeted the entire complement of human protein kinases (713 in total, collectively referred to as 
the kinome), and assayed for cell viability. Due to the heterogeneity of human cell lines, the authors 
also carried out a similar kinome siRNA screen using 5 low-passage, murine squamous cell 
carcinoma cell lines (MSCC), which were obtained from mice harboring mutations in p53 pathway 
genes (Atm, Prkdc, p19Arf and Trp53 itself), that were subjected to chemical carcinogens to induce 
squamous cell carcinoma (SCC). 38 out of the 508 kinases shared between human and mouse cells 
were selected for further studies based on several criteria, such as effects of siRNA knockdown on 
viability of both human and mouse SCC, p53 mutational status and metastatic potential. Kinases for 
which inhibition impaired viability of human foreskin fibroblasts were excluded, leaving 28 kinases for 
follow-up studies. Secondary screening of additional HSNCC lines with independent siRNAs using 
viability and programmed cell death as endpoints confirmed a set of 10 kinases as essential for 
cancer cell survival. 
To corroborate the siRNA data and to identify compounds for in vivo testing, the researchers tes ted 
small molecule inhibitors targeting 6 kinases. AZD1775, a small molecule inhibitor of the WEE1  
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kinase, had the broadest and most potent effect. Since WEE1 is a kinase that regulates the G2/M 
transition of the cell cycle, the authors hypothesized that p53-deficient SCC cells were particularly 
dependent on the G2/M checkpoint. To test this, they performed flow cytometry experiments that 
demonstrated that inhibition of WEE1 by AZD1775 resulted in unscheduled entry into the cell cycle 
and programmed cell death. Finally, to ascertain the therapeutic potential for WEE1 inhibition in a 
preclinical model, the investigators carried out a four arm, double blind study using a HSNCC cell 
line with high metastatic potential, which demonstrated that AZD1775 potentiates the efficacy of 
cisplatin, the standard chemotherapeutic agent for HSNCC. "We identified a number of potential 
kinase targets and focused on the G2/M cell cycle regulator WEE1.  Inhibition of WEE1 with a small 
molecule inhibitor AZD1775 was effective against tumors in mice.  These studies directly led to a 
phase I clinical trial in head and neck cancer patients", summarized Dr. Méndez. 
Overall, this study demonstrated that a collaborative effort can rapidly drive a basic research project 
to a clinical trial and demonstrated the feasibility of exploiting vulnerabilities of cancers cells in the 
clinic. This approach could lead to better therapies not only for head and neck cancers, but also for 
other, difficult-to -treat cancers. 
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Image provided by Mr. Russell Moser. 
Identification of survival kinases in squamous cell carcinoma (SCC) 
using comparative functional kinomics. Top panel: drug sensitivity of 
p53 wild-type, p53 wild-type positive for human papilloma virus and 
p53 mutant SCC cells to chemical inhibition of G2/M kinases. 
Bottom left: differential cell viability in RNA interference validation 
screens. Bottom right: Cartesian plot of Z-scores from interspecies 
kinome identified kinases with highest shared impact on cell 
viability. 
 
